Is Ascletis Pharma (SEHK:1672) Undervalued On FDA Clearance For ASC35?

Ascletis Pharma (SEHK:1672) has attracted investor attention after receiving U.S. FDA Investigational New Drug clearance for ASC35, a once-monthly dual GLP-1/GIP agonist that is being advanced into a Phase I obesity trial.

See our latest analysis for Ascletis Pharma.

The FDA IND clearance arrives after a volatile year for Ascletis Pharma, with the share price down 35.2% over the past month and 37.9% over three months, while still delivering a 3-year total shareholder return of 418.5% and a 5-year total shareholder return of 186.4%.

If ASC35 has sharpened your interest in obesity and metabolic treatments, you may also want to scan other healthcare AI opportunities via our 127 healthcare AI stocks.

With Ascletis Pharma shares sharply lower in recent months yet trading at a large discount to the HK$24.01 analyst price target, you have to ask whether the weakness is overdone or whether the market is already counting on ASC35 success.

Preferred Price-to-Book Multiple of 4.8x: Is It Justified?

Ascletis Pharma last closed at HK$10.11, while its current valuation on a price-to-book basis sits at 4.8x. This screens as good value compared to similar companies but expensive relative to the broader Hong Kong biotechs sector.

The price-to-book, or P/B, ratio compares a company’s market value with the book value of its net assets on the balance sheet. For a research heavy biotech like Ascletis Pharma, which is currently unprofitable and reports very limited revenue of roughly CN¥2m, the P/B ratio often becomes one of the clearer ways to see how much investors are paying for its pipeline, intellectual property and future potential instead of current earnings.

According to the data provided, Ascletis Pharma’s P/B ratio of 4.8x is described as good value compared with a peer group average of 23.9x. This suggests investors are paying far less for each unit of book value than for those peers. However, the same 4.8x multiple is described as expensive against the wider Hong Kong biotechs industry average P/B of 3.2x, indicating the stock is priced at a premium to the broader sector even though the company is currently loss making and reports declining annual revenue and earnings forecasts. Without a fair ratio estimate or a DCF cross check, the market could still move in either direction if views on the portfolio or profitability outlook shift.

In short, Ascletis Pharma trades on a P/B that sits between its direct high multiple peers and the lower rated Hong Kong biotechs sector. This leaves investors weighing its current losses, small reported revenue base and expected path to profitability against that premium.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 4.8x (ABOUT RIGHT)

However, the Ascletis Pharma story could shift quickly if obesity or antiviral programs hit clinical setbacks, or if ongoing losses of CN¥359.88m widen further.

Find out about the key risks to this Ascletis Pharma narrative.

Next Steps

If this combination of opportunity and concern around Ascletis Pharma leaves you uncertain, consider promptly reviewing the underlying data and weighing the risks yourself, starting with its 2 important warning signs.

Looking for more investment ideas beyond Ascletis Pharma?

Do not stop with Ascletis Pharma. Broaden your watchlist quickly with a few focused stock ideas that could sharpen your portfolio thinking and highlight fresh opportunities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com